These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 23093613)

  • 41. Intravenous thrombolysis for patients with reverse magnetic resonance angiography and diffusion-weighted imaging mismatch: SAMURAI and NCVC rt-PA Registries.
    Sakamoto Y; Koga M; Kimura K; Nagatsuka K; Okuda S; Kario K; Hasegawa Y; Okada Y; Yamagami H; Furui E; Nakagawara J; Shiokawa Y; Okata T; Kobayashi J; Tanaka E; Minematsu K; Toyoda K
    Eur J Neurol; 2014 Mar; 21(3):419-26. PubMed ID: 24261412
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined intravenous and intraarterial revascularization therapy using MRI perfusion/diffusion mismatch selection for acute ischemic stroke at 3-6 h after symptom onset.
    Han MK; Kim SH; Ko SB; Paik NJ; Kwon OK; Lee YS; Oh CW; Kim JH; Park SH; Bae HJ
    Neurocrit Care; 2008; 8(3):353-9. PubMed ID: 18340411
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clot burden score on admission T2*-MRI predicts recanalization in acute stroke.
    Legrand L; Naggara O; Turc G; Mellerio C; Roca P; Calvet D; Labeyrie MA; Baron JC; Mas JL; Meder JF; Touzé E; Oppenheim C
    Stroke; 2013 Jul; 44(7):1878-84. PubMed ID: 23704103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials.
    Thomalla G; Schwark C; Sobesky J; Bluhmki E; Fiebach JB; Fiehler J; Zaro Weber O; Kucinski T; Juettler E; Ringleb PA; Zeumer H; Weiller C; Hacke W; Schellinger PD; Röther J;
    Stroke; 2006 Mar; 37(3):852-8. PubMed ID: 16439696
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reperfusion and outcomes in Penumbra vs. systemic tissue plasminogen activator clinical trials.
    Alexandrov AV; Schellinger PD; Saqqur M; Barreto A; Demchuk AM; Ribo M; Rubiera M; Sharma VK; Heliopoulos I; Alexandrov AW; Molina CA; Tsivgoulis G;
    Int J Stroke; 2011 Apr; 6(2):118-22. PubMed ID: 21371272
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does symptom onset to primary stroke center time goals affect stroke outcome?
    Chee B; Raman R; Ernstrom K; Guzik AK; Hemmen TM; Rapp KS; Meyer BC; Meyer DM
    J Stroke Cerebrovasc Dis; 2014; 23(5):993-1000. PubMed ID: 24103670
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retrospective multicenter study of Solitaire FR for revascularization in the treatment of acute ischemic stroke.
    Dávalos A; Pereira VM; Chapot R; Bonafé A; Andersson T; Gralla J;
    Stroke; 2012 Oct; 43(10):2699-705. PubMed ID: 22851547
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.
    Davis SM; Donnan GA; Parsons MW; Levi C; Butcher KS; Peeters A; Barber PA; Bladin C; De Silva DA; Byrnes G; Chalk JB; Fink JN; Kimber TE; Schultz D; Hand PJ; Frayne J; Hankey G; Muir K; Gerraty R; Tress BM; Desmond PM;
    Lancet Neurol; 2008 Apr; 7(4):299-309. PubMed ID: 18296121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital.
    Hsu YC; Sung SF; Ong CT; Wu CS; Su YH
    Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Endovascular treatment of acute ischemic stroke may be safely performed with no time window limit in appropriately selected patients.
    Abou-Chebl A
    Stroke; 2010 Sep; 41(9):1996-2000. PubMed ID: 20651271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke.
    Lansberg MG; Thijs VN; Bammer R; Kemp S; Wijman CA; Marks MP; Albers GW;
    Stroke; 2007 Aug; 38(8):2275-8. PubMed ID: 17569874
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Every 15-min delay in recanalization by intra-arterial therapy in acute ischemic stroke increases risk of poor outcome.
    He AH; Churilov L; Mitchell PJ; Dowling RJ; Yan B
    Int J Stroke; 2015 Oct; 10(7):1062-7. PubMed ID: 25918863
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the DEFUSE study.
    Marks MP; Olivot JM; Kemp S; Lansberg MG; Bammer R; Wechsler LR; Albers GW; Thijs V;
    Radiology; 2008 Nov; 249(2):614-23. PubMed ID: 18936316
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke.
    Rubiera M; Alvarez-Sabín J; Ribo M; Montaner J; Santamarina E; Arenillas JF; Huertas R; Delgado P; Purroy F; Molina CA
    Stroke; 2005 Jul; 36(7):1452-6. PubMed ID: 15947260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
    Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Baseline National Institutes of Health stroke scale-adjusted time window for intravenous tissue-type plasminogen activator in acute ischemic stroke.
    Muchada M; Rubiera M; Rodriguez-Luna D; Pagola J; Flores A; Kallas J; Sanjuan E; Meler P; Alvarez-Sabin J; Ribo M; Molina CA
    Stroke; 2014 Apr; 45(4):1059-63. PubMed ID: 24603070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion.
    Alvarez-Sabín J; Molina CA; Ribó M; Arenillas JF; Montaner J; Huertas R; Santamarina E; Rubiera M
    Stroke; 2004 Nov; 35(11):2493-8. PubMed ID: 15472110
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Large-Vessel Occlusion Stroke: Effect of Recanalization on Outcome Depends on the National Institutes of Health Stroke Scale Score.
    Skagen K; Skjelland M; Russell D; Jacobsen EA
    J Stroke Cerebrovasc Dis; 2015 Jul; 24(7):1532-9. PubMed ID: 25922156
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous alteplase at 0.6 mg/kg for acute stroke patients with basilar artery occlusion: the stroke acute management with urgent risk factor assessment and improvement (SAMURAI) Recombinant tissue plasminogen activator registry.
    Miyagi T; Koga M; Shiokawa Y; Nakagawara J; Hasegawa Y; Furui E; Kimura K; Kario K; Okuda S; Yamagami H; Okada Y; Nezu T; Maeda K; Endo K; Minematsu K; Toyoda K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1098-106. PubMed ID: 23063059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment with tPA predicts better outcome even if MCA occlusion persists.
    Kablau M; Alonso A; Hennerici MG; Fatar M
    Int J Stroke; 2013 Oct; 8(7):496-502. PubMed ID: 22340025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.